Treatment-resistant schizophrenia is a major health problem in the UK with the majority of patients treated with clozapine. In up to 70% of cases there is only a partial response to clozapine with continuing refractory symptoms. We describe two cases in a UK mental health service where minocycline was found to be useful and well tolerated as an augmentation agent with clozapine in the improvement of previously resistant positive and negative symptoms.
FanXet al. (2007) Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia. Psychiatry Res149: 267–271.
4.
KellyDet al. (2011) Adjunct minocycline to clozapine treated patients with persistent schizophrenia symptomsSchizophr Res133: 257–258.
5.
LevkovitzYet al. (2007) Minocycline, a second-generation tetracycline, as a neuroprotective agent in an animal model of schizophrenia. Brain Res1154: 154–162.
6.
MiyaokaT (2008a) Minocycline as adjunctive therapy for schizophrenia: An open-label study. Clin Neuropharmacol31: 287–292.
7.
MiyaokaT (2008b) Clinical potential of minocycline for schizophrenia. CNS Neurol Disord Drug Targets7: 376–381.
8.
SommerEet al. (2001) Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: A quantitative literature review. Schizophr Bull38:1003–1011.
9.
ZhangLet al. (2004) Minocycline attenuates hyperlocomotion and prepulse inhibition deficits in mice after administration of the NMDA receptor antagonist dizocilpine. Neuropsychopharmacology32: 2004–2010.
